Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial - Université de Lorraine Access content directly
Journal Articles The Lancet Year : 2022

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Filip Baert
  • Function : Author
Allen Lim
  • Function : Author

Abstract

There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody, was efficacious and well tolerated as induction therapy. Here, we report the efficacy and safety of subcutaneous risankizumab as maintenance therapy.
AbbVie.
No file

Dates and versions

hal-04165779 , version 1 (19-07-2023)

Identifiers

Cite

Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, et al.. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. The Lancet, 2022, 399 (10340), pp.2031-2046. ⟨10.1016/S0140-6736(22)00466-4⟩. ⟨hal-04165779⟩
12 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More